How Much Rooster Comb Injections Cost With Insurance

Rooster comb injections, the common name for hyaluronic acid (HA) viscosupplementation shots given for knee osteoarthritis, typically cost between $300 and $1,000 or more per injection at full price, but what you actually pay with insurance depends heavily on your plan type, the specific product your doctor uses, and whether your insurer considers the treatment medically necessary. Medicare Part B has covered these injections for years, and many private insurers do as well, though coverage has become harder to secure after major orthopedic guidelines questioned their value. The real-world out-of-pocket cost for an insured patient can range from a modest copay to the full sticker price if the claim is denied.

What “Rooster Comb” Injections Actually Are

The nickname comes from the original manufacturing process. Hyaluronic acid, a naturally occurring substance in joint fluid that helps cushion and lubricate the knee, was historically extracted from the combs of roosters. Today, some products still use this avian-derived HA, while others are made through bacterial fermentation, eliminating the animal component entirely. Regardless of the source, the goal is the same: inject a gel-like substance into the knee joint to restore some of the cushioning that osteoarthritis has worn away.

Viscosupplementation works by supplementing the thinned-out joint fluid with fresh hyaluronic acid, which restores some of the natural shock-absorbing quality. Beyond the mechanical cushioning effect, HA has also been shown to dial down inflammatory activity inside the joint itself.

Because these injections originally came from avian tissue, people with egg or poultry allergies need to flag that before treatment. Avian-derived products carry a small risk of allergic reaction from residual animal protein, though the risk is rare.

The Price Tag Before Insurance Gets Involved

Several FDA-approved HA products exist for knee osteoarthritis, and their prices vary widely. Some require a single injection per treatment course, while others involve three to five weekly shots. A single-injection product like Synvisc-One or Gel-One might carry a list price of $700 to $1,200 for the one visit. A three-injection series using products like Euflexxa or Supartz could run $600 to $2,500 for the full course, depending on the product and the clinic’s markup. On top of the drug cost, you are billed separately for the office visit and the injection procedure itself.

Doctors bill HA injections using specific procedure and drug codes. The injection procedure code (CPT 20610, for a large joint injection) gets billed alongside a product-specific code, and there are several of these codes corresponding to different HA formulations.

Knowing the codes your doctor plans to bill can help if you need to call your insurer ahead of time to confirm coverage or file an appeal after a denial.

What Medicare Pays

Medicare Part B has covered viscosupplementation for knee osteoarthritis, and the program remains one of the largest payers for these injections in the United States. Between 2012 and 2018, total Medicare spending on HA services rose from about $290 million to $325 million, even as the debate over their clinical value intensified.

⁴

Under Medicare Part B, you typically pay 20% of the Medicare-approved amount after meeting your Part B deductible. If the approved amount for the drug plus the injection runs $500, your share would be $100. If you have a Medicare Supplement (Medigap) plan, that 20% coinsurance may be covered as well, potentially reducing your out-of-pocket cost to little or nothing beyond the plan premium. Medicare Advantage plans set their own cost-sharing rules, so the copay can differ significantly from traditional Medicare.

One thing worth noting: Medicare’s continued coverage does not mean the program enthusiastically endorses the treatment. The sheer volume of Medicare beneficiaries receiving HA injections, over 1.2 million in 2018, reflects a combination of patient demand, physician practice patterns, and the fact that Medicare has not placed the same restrictions on coverage that some private insurers have.

⁴

Private Insurance and the Prior Authorization Problem

Private insurance coverage for HA knee injections is less predictable than Medicare. Many commercial plans do cover viscosupplementation, but they increasingly require prior authorization, meaning your doctor has to submit documentation justifying the treatment before the insurer agrees to pay. Common requirements include proof that you have tried and failed other conservative treatments first, such as over-the-counter pain relievers, physical therapy, and corticosteroid injections.

Here is where things get complicated. The American Academy of Orthopaedic Surgeons (AAOS) issued clinical practice guidelines that expressed skepticism about the value of HA injections, and some private insurers have used those guidelines as justification for restricting or denying coverage. After the AAOS published its recommendations, the rate of HA injection use measurably declined, and insurers took notice.

⁵

If your plan denies coverage citing those guidelines, you are looking at the full out-of-pocket cost, which can easily exceed $1,000 for a treatment course.

When a claim is denied, you have the right to appeal. Appeals are more likely to succeed when your doctor documents that other treatments have failed, that you are not a good candidate for knee replacement surgery, and that HA injections are being used to manage pain and maintain function in a specific clinical context. Some patients find success on appeal; others do not. The outcome often depends on the specific insurer, the state you live in, and how aggressively your doctor’s office pursues the paperwork.

Why the Clinical Controversy Matters for Your Wallet

The scientific debate over whether these injections work well enough to justify their cost is not just academic. It directly affects what you pay. The AAOS guidelines described the injections as having “questionable clinical efficacy” relative to their high cost, and recommended against routine use.

⁵

This recommendation carried weight because the AAOS is the primary professional organization for orthopedic surgeons in the U.S., and insurers often align their coverage policies with major medical society guidelines.

That said, the picture is not as simple as “the evidence says they don’t work.” Many patients report meaningful pain relief, and the clinical trial data, while mixed, does show some benefit for a subset of people. The debate is more about whether the benefit is large enough to justify the cost compared to cheaper alternatives like corticosteroid shots or anti-inflammatory medications. Cost comparisons generally show that the annual expense of HA treatment is roughly comparable to taking a daily anti-inflammatory drug with a stomach-protective medication, but more expensive than periodic corticosteroid injections.

⁶

For patients caught in the middle of this debate, the practical implication is straightforward: your insurer may agree with the AAOS and limit coverage, or may follow other guidelines that view HA more favorably. Checking your specific plan’s formulary and medical policy before scheduling the injection can save you a surprise bill.

How Product Choice Affects What You Pay

Not all HA products carry the same price, and the one your doctor selects can make a real difference in your copay or coinsurance. Single-injection products tend to have a higher per-visit drug cost but eliminate the need for return visits, which saves on repeated office visit copays and the time cost of multiple appointments. Three-to-five injection series have a lower per-dose drug price but accumulate costs across several visits.

Your insurer may also have a preferred product. Just as insurance plans have drug formularies that favor generic medications over brand-name ones, some plans steer patients toward specific HA products that the insurer has negotiated a better rate on. If your doctor prescribes a non-preferred product, you could face a higher copay or full denial. Asking your doctor whether they can use a plan-preferred product, if one exists, is a practical move that can cut your cost without changing the fundamental treatment.

The provider setting matters too. An injection administered in a hospital outpatient department is almost always billed at a higher facility rate than the same injection given in a private orthopedic office. If you have a choice, the in-office route generally means lower cost-sharing.

Can These Injections Delay Knee Replacement?

One argument in favor of covering viscosupplementation, despite the clinical debate, is that it may postpone the need for total knee replacement surgery, which costs tens of thousands of dollars. Several large studies using insurance claims data have found that patients who receive HA injections do tend to go longer before undergoing knee replacement.

One analysis found that receiving at least one HA injection was associated with delaying knee replacement by roughly seven months over a seven-and-a-half-year period compared to patients who never received HA.

⁷

Another study using a large U.S. health claims database found a dose-dependent relationship: patients who received five or more courses of HA injections delayed knee replacement by an average of about 3.6 years compared to patients who received none.

⁸

A separate study comparing HA injections to corticosteroid injections found that both delayed surgery compared to no injections at all. Patients who received HA waited roughly 671 days from diagnosis to surgery, versus about 342 days for patients who received no injections. Corticosteroid injections performed similarly in terms of initial delay, though with repeated injections, corticosteroids appeared to offer a slightly larger delay per additional course than HA did.

⁹

These findings do not prove that HA injections are the reason for the delay, as observational studies cannot establish causation. Patients who opt for injections may differ from those who go straight to surgery in ways the data cannot fully capture. Still, the pattern is consistent enough that some physicians and patients use it as part of their argument to insurers: covering injections now may save the plan money by pushing back the date of a far more expensive surgery.

Off-Label Joints and Coverage Gaps

Most HA products are FDA-approved specifically for knee osteoarthritis, which means insurance coverage is typically limited to that joint. If your doctor recommends HA injections for your hip, shoulder, or ankle, you are entering off-label territory. Off-label use is legal and common in medicine, but insurers are under no obligation to cover it, and many do not.

Hip osteoarthritis is a particularly relevant example. Conservative treatments for hip OA, including HA injections, physical therapy, and pain medications, can account for a substantial share of healthcare costs in the year before hip replacement surgery. One analysis of Medicare and commercial insurance data found that conservative treatments made up about 40 to 44 percent of total costs in the year before hip replacement.

⁹

But because HA is not FDA-approved for the hip, getting insurance to pay for hip viscosupplementation usually requires a more aggressive prior authorization effort, and denial rates are higher. Patients receiving HA in the hip or shoulder should expect the possibility of paying out-of-pocket.

Practical Steps to Minimize Your Cost

If you are considering viscosupplementation and want to keep your expenses manageable, a few concrete steps can help:

Call your insurer first: Ask specifically whether viscosupplementation is covered under your plan for your diagnosis, and whether prior authorization is required. Get the answer in writing if possible.
Ask about preferred products: If your plan covers HA but has a preferred formulary product, using that product can lower your copay or coinsurance.
Choose an office setting: Receiving the injection in a doctor’s office rather than a hospital outpatient department almost always reduces the facility fee, which lowers your cost-sharing.
Document failed alternatives: If prior authorization is required, your doctor should document that you have tried and failed physical therapy, over-the-counter medications, and possibly corticosteroid injections. This paper trail strengthens the case.
Know your appeal rights: If coverage is denied, you can appeal. Your doctor’s office can often handle this, but you may need to be persistent. Some states have external review processes that provide an independent evaluation of the denial.

When Corticosteroid Injections Make More Financial Sense

For many patients, the most immediate cost comparison is not HA versus surgery but HA versus corticosteroid injections. Corticosteroid shots are dramatically cheaper. A single cortisone injection might cost $50 to $300 total, and insurance coverage is rarely disputed because corticosteroids are an established first-line treatment for joint inflammation. HA injections, by contrast, come with a higher price tag and a more complicated insurance landscape.

Clinically, the two treatments work differently. Corticosteroids reduce inflammation and provide relatively fast pain relief that typically lasts a few weeks to a couple of months. HA injections take longer to kick in but may provide relief lasting several months. The cost comparison is clear: HA is more expensive per course than corticosteroids.

⁶

For patients whose insurance readily covers cortisone but balks at HA, starting with corticosteroids and documenting your response is often the most practical path. If cortisone stops providing adequate relief, that documented failure becomes your strongest argument for HA coverage.

Some patients also alternate between the two. A corticosteroid injection for acute flares and HA for longer-term maintenance is a pattern some physicians use, though insurance may not cover both in quick succession. Spacing them out and keeping clear records of what was administered and when helps avoid billing complications.

The Avian-Source Question and Newer Products

The “rooster comb” name persists even though the market has shifted. Several newer HA products are produced through bacterial fermentation rather than avian extraction. For patients with egg or poultry allergies, these non-avian products eliminate the theoretical risk of an allergic reaction to residual bird protein.

From a cost perspective, the manufacturing source does not consistently drive price differences. Both avian-derived and bacterially fermented products span a range of prices, and insurers generally do not differentiate coverage based on the HA source. The choice between avian and non-avian products is primarily a clinical and safety consideration, not a financial one, unless your doctor specifically recommends a product that happens to fall outside your plan’s formulary.

If you have a known poultry allergy, make sure your doctor knows before scheduling the injection. The non-avian alternatives are widely available and work through the same mechanism, so switching products is straightforward in most cases. Your out-of-pocket cost should not change much either way, as long as the substitute product is also covered by your plan.

1
PubMed Central. A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee
2
PubMed. Hylaform: a new hyaluronic acid filler
3
PubMed Central. Using Medicare Data to Understand Low-value Health Care: The Case of Intra-articular Hyaluronic Acid Injections
4
Journal of Bone and Joint Surgery. Hyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018?
5
Journal of Bone and Joint Surgery. Impact of Clinical Practice Guidelines on Use of Intra-Articular Hyaluronic Acid and Corticosteroid Injection for Knee Osteoarthritis
6
PubMed Central. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis
7
PubMed Central. Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis – A Cox model analysis
8
PLOS ONE. Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database
9
PubMed Central. Analysis of the Cost and Efficacy of Intra-Articular Knee Injections